The tentative preferred drug list review schedule for the Jan. 26, 2024, Texas Drug Utilization Review Board is available.
Drug Classes
- Acne Agents, oral
- Acne Agents, topical
- Analgesics, Narcotics Long
- Analgesics, Narcotics Short
- Angiotensin Modulator Combinations
- Angiotensin Modulators
- Antihypertensives, Sympatholytic
- Antimigraine Agents, other
- Antimigraine Agents, triptans
- Antiparkinsons Agents
- Bladder Relaxant Preparations
- Glucagon Agents
- H. Pylori Treatment
- Intranasal Rhinitis Agents
- Movement Disorders
- Neuropathic Pain
- Oncology, Oral - Breast
- Oncology, Oral - Hematologic
- Oncology, Oral - Lung
- Oncology, Oral - Other
- Oncology, Oral - Prostate
- Oncology, Oral - Renal Cell
- Oncology, Oral - Skin
- PAH Agents, Oral and Inhaled
- Pancreatic Enzymes
- Phosphate Binders
- Platelet Aggregation Inhibitors
- Potassium Binders
- Progestins for Cachexia
- Proton Pump Inhibitors
- Smoking Cessation
- Stimulants and Related Agents
Single Drugs / PDL Classes
- Rykindo (intramuscular) / Antipsychotics
- Adalimumab-Adbm Kit (Injection) (CF) 50 mg/ml / Cytokine and CAM Antagonists
- Adalimumab-Adbm Pen Kit (Injection) (CF) 50 mg/ml / Cytokine and CAM Antagonists
- Entyvio Pen (subcutane.) / Cytokine and CAM Antagonists
- Jesduvroq Tablet (oral) / Erythropoiesis Stimulating Proteins
- Airsupra Hfa (inhalation) / Glucocorticoids, Inhaled
- Ojjaara (oral) / Oncology, Oral - Hematologic
- Akeega (oral) / Oncology, Oral - Prostate
- Narcan Spray OTC (nasal) / Opiate Dependence Treatments
- Motpoly XR (oral) / Anticonvulsants